No Data
Taysha Gene Therapies Analyst Ratings
CCORF Maintains Taysha Gene Therapies(TSHA.US) With Buy Rating, Raises Target Price to $8
Taysha Gene Therapies Price Target Maintained With a $6.00/Share by Needham
Taysha Gene Therapies Shares Are Trading Higher. Cantor Fitzgerald Reiterated an Overweight Rating on the Stock.
Hillenbrand Posts Better-Than-Expected Earnings, Joins Beazer Homes, Tapestry, Walt Disney And Other Big Stocks Moving Higher On Thursday
Cantor Fitzgerald Maintains Taysha Gene Therapies(TSHA.US) With Buy Rating, Maintains Target Price $7
No Data
No Data